¼¼°èÀÇ ´ÙÇÑÁõ Ä¡·á ½ÃÀå
Hyperhidrosis Treatment
»óǰÄÚµå : 1774931
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 480 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ´ÙÇÑÁõ Ä¡·á ½ÃÀåÀº 2030³â±îÁö 8¾ï 7,270¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 6¾ï 8,610¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ´ÙÇÑÁõ Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 4.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 8¾ï 7,270¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °Üµå¶ûÀÌ ´ÙÇÑÁõ À¯ÇüÀº CAGR 5.0%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 4¾ï 2,650¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼Õ¹Ù´Ú ´ÙÇÑÁõ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 2.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 8,690¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ÙÇÑÁõ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 1¾ï 8,690¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 7,960¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.7%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.6%¿Í 3.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.4%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ´ÙÇÑÁõ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

´ÙÇÑÁõ Ä¡·á°¡ ÀÇ·á°è¿Í ¼ÒºñÀÚÀÇ ÁÖ¸ñÀ» ¹Þ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

´ÙÇÑÁõÀº °úµµÇϰí Á¾Á¾ ¿¹ÃøÇÒ ¼ö ¾ø´Â ¹ßÇÑÀ» Ư¡À¸·Î ÇÏ´Â ÁúȯÀ¸·Î, »îÀÇ Áú¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ ÀÇ·á°è¿Í ÀÏ¹Ý ¼ÒºñÀÚµé »çÀÌ¿¡¼­ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Àü ¼¼°è Àα¸ÀÇ 2-5%°¡ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ´Â ÀÌ ÁúȯÀº ±¹¼ÒÀû(±¹¼Ò ´ÙÇÑÁõ)°ú Àü½ÅÀû(Àü½Å ´ÙÇÑÁõ)À¸·Î ³ª´µ¸ç, Á¾Á¾ »çȸÀû ¼öÄ¡½É, Á¤½ÅÀû °íÅë, Á÷¾÷Àû Á¦ÇÑÀ¸·Î À̾îÁý´Ï´Ù. ¿ª»çÀûÀ¸·Î °ú¼Ò Áø´Ü, °ú¼Ò Ä¡·áµÇ¾ú´ø ´ÙÇÑÁõÀº ÀÌÁ¦ ´Ü¼øÇÑ ¹Ì¿ë»óÀÇ ¹®Á¦°¡ ¾Æ´Ñ Á¤´çÇÑ ÀÇÇÐÀû ¹®Á¦·Î Àνĵǰí ÀÖ½À´Ï´Ù. ÀÎ½Ä °³¼± Ä·ÆäÀÎ, ´õ ³ªÀº Áø´Ü µµ±¸, Àü¹®°¡ÀÇ µµ¿òÀ» ¹ÞÀ¸·Á´Â ȯÀÚµéÀÇ ÀÇÁö°¡ ³ô¾ÆÁü¿¡ µû¶ó ´õ ¸¹Àº ȯÀÚµéÀÌ °¡´ÉÇÑ Ä¡·á¹ýÀ» ã°Ô µÇ¾ú½À´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû, ¿ø°Ý ÇǺΰú, ÀǾàǰ ¸¶ÄÉÆÃÀ» ÅëÇØ ´ÙÇÑÁõ¿¡ ´ëÇÑ Æí°ßÀÌ ÁÙ¾îµé°í Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ °³¼±µÊ¿¡ µû¶ó ´ÙÇÑÁõÀº ÇǺΰú ¹× ¹Ì¿ë ÀÇ·áÀÇ ¿ì¼± ¼øÀ§ ºÐ¾ß·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀÇ º¯È­·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ÀÇ·á ¹× Àúħ½ÀÀû Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±â¼ú°ú ÀǾàǰÀÇ ¹ßÀüÀº ¾î¶»°Ô Ä¡·á ¿É¼ÇÀ» Çü¼ºÇϰí Àִ°¡?

±â¼ú ¹× ÀǾàǰÀÇ ¹ßÀüÀ¸·Î ´ÙÇÑÁõ Ä¡·á¹ýÀÌ ±ØÀûÀ¸·Î È®´ëµÇ¾î ȯÀڵ鿡°Ô º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÌ¸ç ¿À·¡ Áö¼ÓµÇ´Â ´ÙÇÑÁõ Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù. º¸Åø¸®´® Åå½Å(º¸Å彺) ÁÖ»ç´Â ¶¡»ùÀ» Ȱ¼ºÈ­½ÃŰ´Â ¾Æ¼¼Æ¿Äݸ°ÀÇ ¹æÃâÀ» Â÷´ÜÇÏ¿© °Üµå¶ûÀÌ, ¼Õ¹Ù´Ú, ¹ß¹Ù´Ú°ú °°Àº ±¹¼Ò ´ÙÇÑÁõÀ» Ä¡·áÇÏ´Â µ¥ ÀÖ¾î ¿©ÀüÈ÷ Ç¥ÁØÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î Á¦Çü°ú ÁÖ»ç ±â¼ú·Î ÀÎÇØ Á¤È®µµ°¡ Çâ»óµÇ°í ºÒÆíÇÔÀÌ ÁÙ¾îµé°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸¿¡¼­´Â Ä¡·á Ƚ¼ö¸¦ ÁÙÀÏ ¼ö ÀÖ´Â Áö¼Ó¼º ½Å°æµ¶ÀÌ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±Û¸®ÄÚÇǷδϿò Åä½Ç·¹ÀÌÆ®¿Í °°Àº ±¹¼Ò Ç×Äݸ°Á¦´Â ¿©·¯ ±¹°¡¿¡¼­ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹Þ¾Æ ÀçÅà ġ·á¸¦ ¿øÇϴ ȯÀڵ鿡°Ô ºñħ½ÀÀû Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¸¶ÀÌÅ©·ÎÆÄ ¿Â¿­¿ä¹ýÀ̳ª À̿¿µµ¿¿ä¹ýÀÇ Çõ½ÅÀº ÃÖ¼ÒÇÑÀÇ ºÎÀÛ¿ëÀ¸·Î Áõ»óÀ» Á¶ÀýÇÒ ¼ö ÀÖ´Â ´ë¾ÈÀ» Á¦°øÇϸç, ³»½Ã°æÀû ÈäºÎ ±³°¨½Å°æ ÀýÁ¦¼ú(ETS)°ú °°Àº ¼ö¼úÀû ¿É¼ÇÀº ÁßÁõ Ä¡·á ÀúÇ×¼º ´ÙÇÑÁõ ȯÀÚ¸¦ À§ÇØ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí, ¶¡ÀÇ ¾çÀ» ¸ð´ÏÅ͸µÇÏ°í ½Ç½Ã°£À¸·Î ±¹¼Ò Ä¡·á¸¦ ÇÏ´Â ¿þ¾î·¯ºí ±â¼úÀÇ °³¹ßÀº ÀÓ»ó½ÃÇè¿¡¼­ À¯¸ÁÇÑ °á°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Ä¡·áÀÇ È¿°ú¿Í ÆíÀǼºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, °³ÀÎÈ­µÈ Ä¡·á ¼Ö·ç¼ÇÀ» ¿øÇÏ´Â ´Ù¾çÇÑ È¯ÀÚÃþÀ¸·Î Ä¡·á ½ÃÀåÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå È®´ë¿¡ ÀÖ¾î ÀÎÁöµµ, »óȯ, ÇǺΰúÀû Á¢±ÙÀº ¾î¶² ¿ªÇÒÀ» ÇÒ °ÍÀΰ¡?

´ÙÇÑÁõÀÌ ´Ü¼øÇÑ ºÒÆíÇÔÀÌ ¾Æ´Ñ Ä¡·á °¡´ÉÇÑ ÁúȯÀ̶ó´Â ÀνÄÀÌ È®»êµÇ¸é¼­ ´ÙÇÑÁõ ½ÃÀå È®´ë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç ³ë·Â, ¿Â¶óÀÎ Áö¿ø Ä¿¹Â´ÏƼ, Á¦¾à»çÀÇ µðÁöÅÐ Ä·ÆäÀÎ µîÀ» ÅëÇØ ´õ ¸¹Àº ȯÀÚµéÀÌ Áõ»óÀ» ÀÎÁöÇϰí Ä¡·á¸¦ ¹ÞÀ¸·Á´Â ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡, ÇǺΰú Àü¹®ÀÇ¿Í 1Â÷ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ÀÌ ÁúȯÀ» ´õ Àß Áø´ÜÇÏ°í °ü¸®ÇÒ ¼ö ÀÖµµ·Ï ±³À°À» ¹Þ°í ÀÖÀ¸¸ç, ÀÇ·ÚÀ²°ú Ä¡·áÀ²ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­´Â º¸Åø¸®´® Åå½Å Áֻ糪 ¿Ü¿ëÁ¦¿Í °°Àº FDA ¹× EMA°¡ ½ÂÀÎÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ º¸Çè »óȯ Á¤Ã¥µµ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª °³¹ßµµ»ó±¹¿¡¼­ÀÇ ÇǺΰú ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼º Á¦ÇѰú »óȯ °ÝÂ÷´Â ¿©ÀüÈ÷ Å« ¹®Á¦À̸ç, ƯÈ÷ ¹Ì¿ëÀû ÁúȯÀ̳ª »ý¸íÀ» À§ÇùÇÏÁö ¾Ê´Â ÁúȯÀÌ ¿ì¼±¼øÀ§°¡ ¾Æ´Ñ °æ¿ì ´õ¿í ±×·¯ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °ÝÂ÷¸¦ ÇØ¼ÒÇϱâ À§ÇØ ±â¾÷µéÀº º¸´Ù Àú·ÅÇÑ ½ÃÆÇ ÀǾàǰÀ» ¸ð»öÇϰí, Áø´Ü ¹× ó¹æ Ä¡·á¿¡ ´ëÇÑ ¿ø°Ý ¾×¼¼½º¸¦ °³¼±ÇÏ´Â µðÁöÅÐ °Ç°­ Ç÷§ÆûÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ »îÀÇ Áú Ä¡·á¸¦ º¸´Ù Á¾ÇÕÀûÀ¸·Î ¸¸µé°í ¿ø°Ý ÀÇ·á°¡ È®»êµÊ¿¡ µû¶ó ´ÙÇÑÁõ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀº ´õ ±¤¹üÀ§ÇÑ »çȸ°æÁ¦Àû, Áö¸®Àû ºÎ¹®¿¡¼­ °³¼±µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

´ÙÇÑÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº?

´ÙÇÑÁõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ÁøÈ­ÇÏ´Â Ä¡·á ¹æ¹ý, ¼ÒºñÀÚ Çൿ, ÀÇ·á ¼­ºñ½º Á¢±Ù¼º°ú °ü·ÃµÈ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ù°, ´ÙÇÑÁõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ³«ÀÎÀÌ »ç¶óÁö¸é¼­ ´õ ¸¹Àº »ç¶÷µéÀÌ ÀÇ·á ±â°üÀ» ã°Ô µÇ¾î ȯÀÚ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µÑ°, ±â¼ú Çõ½Å, ƯÈ÷ ºñħ½ÀÀû, Àúħ½ÀÀû Ä¡·á Á¢±Ù¹ýÀÌ ÅëÁõ, ºÎÀÛ¿ë, ¼ö¼ú¿¡ ´ëÇÑ µÎ·Á¿òÀ¸·Î Ä¡·á¸¦ ²¨¸®´ø ȯÀÚµéÀ» ²ø¾îµéÀ̰í ÀÖ½À´Ï´Ù. ¼Â°, ¹Ì¿ë ÇǺΰú ¼­ºñ½ºÀÇ µµÀÔÀÌ ÁøÇàµÇ¸é¼­ ¹Ì¿ë Áø·á¿Í ÀÇ·á Áø·á°¡ °ãÄ¡¸é¼­ º¸Å彺¿Í °°Àº °í±Þ Ä¡·á¹ýÀ» ÀÏ»óÀûÀÎ Ä¡·á¿¡ »ç¿ëÇÏ´Â °ÍÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ³Ý°, Á¦¾àȸ»ç´Â ±¹¼Ò ´ÙÇÑÁõ ¹× Àü½Å ´ÙÇÑÁõÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ Â÷¼¼´ë ±¹¼Ò Á¦Á¦ ¹× ¼­¹æÇü Ä¡·áÁ¦¿¡ ÅõÀÚÇÏ¿© ÆíÀǼº°ú ȯÀÚ ¼øÀÀµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ´Ù¼¸Â°, ÀÇ·á º¸Çè Àû¿ë ¹üÀ§ÀÇ È®´ë, ¿ø°Ý ÀÇ·á ³×Æ®¿öÅ©ÀÇ È®´ë, ¼ÒºñÀÚ Á÷Á¢ µðÁöÅÐ °Ç°­ ºê·£µåÀÇ ºÎ»óÀ¸·Î ´ÙÇÑÁõ Ä¡·á´Â ±× ¾î´À ¶§º¸´Ù ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ´ÙÇÑÁõ Ä¡·á ½ÃÀåÀº ȯÀÚµéÀÇ ±â´ë°¡ ÃÑüÀûÀÌ°í »îÀÇ ÁúÀ» Áß½ÃÇÏ´Â ÀÇ·á ¼­ºñ½º·Î À̵¿ÇÔ¿¡ µû¶ó Çõ½Å, ÀÎÁöµµ, ÀÇÇÐÀû °ËÁõ Áõ°¡¿¡ ÈûÀÔ¾î Áö¼ÓÀûÀÎ ¼ºÀå¼¼¸¦ À̾ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

À¯Çü(°Üµå¶ûÀÌ ´ÙÇÑÁõ À¯Çü, ¼Õ¹Ù´Ú ´ÙÇÑÁõ À¯Çü, Á·Àú ´ÙÇÑÁõ À¯Çü, ±âŸ À¯Çü), Ä¡·á(±¹¼Ò Ä¡·á, ³»º¹¾à Ä¡·á, º¸Åø¸®´®Åå½Å(º¸Å彺) ÁÖ»ç Ä¡·á, ÀÌ¿ÂÆ®Æ÷·¹À̽ýº Ä¡·á, ¿Ü°ú Ä¡·á), ¿¬·É(50¼¼ ¹Ì¸¸, 50¼¼ ÀÌ»ó), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ÃÖÁ¾»ç¿ëÀÚ, ÇǺΰú Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°è °íÀ¯ SLM¿¡ Äõ¸®-ÇÏ´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Hyperhidrosis Treatment Market to Reach US$872.7 Million by 2030

The global market for Hyperhidrosis Treatment estimated at US$686.1 Million in the year 2024, is expected to reach US$872.7 Million by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Axillary Hyperhidrosis Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$426.5 Million by the end of the analysis period. Growth in the Palmar Hyperhidrosis Type segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$186.9 Million While China is Forecast to Grow at 7.7% CAGR

The Hyperhidrosis Treatment market in the U.S. is estimated at US$186.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$179.6 Million by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Hyperhidrosis Treatment Market - Key Trends & Drivers Summarized

Why Is Hyperhidrosis Treatment Gaining Increased Medical and Consumer Attention?

Hyperhidrosis, a condition characterized by excessive and often unpredictable sweating, is garnering more attention in medical circles and public awareness due to its substantial impact on quality of life. Affecting an estimated 2-5% of the global population, this condition can be localized (focal hyperhidrosis) or generalized, and it often leads to social embarrassment, emotional distress, and occupational limitations. Historically underdiagnosed and undertreated, hyperhidrosis is now being more frequently recognized as a legitimate medical issue rather than merely a cosmetic concern. Increased awareness campaigns, better diagnostic tools, and the growing willingness of patients to seek professional help are driving more individuals to explore available treatments. As the stigma around excessive sweating decreases and the visibility of treatment options improves-through online platforms, teledermatology, and pharmaceutical marketing-hyperhidrosis is emerging as a priority area in dermatology and aesthetic medicine. This shift in perception is expanding demand for both medical and minimally invasive treatment solutions worldwide.

How Are Technological and Pharmaceutical Advances Reshaping Treatment Options?

Technological and pharmaceutical advancements are dramatically broadening the treatment landscape for hyperhidrosis, offering patients safer, more effective, and longer-lasting relief. Botulinum toxin (Botox) injections remain a gold standard for treating focal hyperhidrosis, particularly in the underarms, palms, and soles, by blocking the release of acetylcholine that activates sweat glands. Newer formulations and injection techniques are improving precision and reducing discomfort, while ongoing research is exploring longer-acting neurotoxins that could reduce the frequency of treatments. Additionally, topical anticholinergic medications such as glycopyrronium tosylate have gained regulatory approvals in several countries, offering a non-invasive alternative for patients seeking at-home management. Innovations in microwave thermolysis and iontophoresis devices are providing alternative routes for symptom control with minimal side effects, while surgical options like endoscopic thoracic sympathectomy (ETS) are being refined for patients with severe, treatment-resistant hyperhidrosis. Meanwhile, the development of wearable technologies that monitor sweat levels and deliver localized therapies in real time is showing promise in clinical trials. These advances are not only improving efficacy and convenience but also expanding the treatment market to a wider patient demographic seeking individualized care solutions.

What Role Do Awareness, Reimbursement, and Dermatological Access Play in Market Expansion?

Growing awareness of hyperhidrosis as a treatable medical condition, rather than a mere inconvenience, is playing a vital role in market expansion. Public health initiatives, online support communities, and digital campaigns from pharmaceutical companies are empowering more patients to recognize symptoms and seek treatment. Simultaneously, dermatologists and primary care providers are being trained to better diagnose and manage the condition, improving referral and treatment rates. Insurance reimbursement policies are also evolving, especially in developed markets, to cover FDA- or EMA-approved treatments like botulinum toxin injections or prescription topical agents-thus lowering financial barriers for patients. However, reimbursement disparities and limited access to dermatological care in developing regions remain significant challenges, particularly where aesthetic or non-life-threatening conditions are deprioritized. To bridge this gap, companies are exploring more affordable, over-the-counter formulations and expanding digital health platforms to improve remote access to diagnosis and prescription treatments. As healthcare systems become more inclusive of quality-of-life treatments and telemedicine gains traction, access to hyperhidrosis care is expected to improve across broader socioeconomic and geographic segments.

What Are the Key Drivers of Growth in the Hyperhidrosis Treatment Market?

The growth in the hyperhidrosis treatment market is driven by several factors related to evolving treatment modalities, consumer behavior, and healthcare accessibility. First, rising awareness and destigmatization of excessive sweating are encouraging more individuals to seek medical consultation, increasing the patient pool. Second, technological innovation-particularly in non-invasive and minimally invasive treatment approaches-is attracting patients who previously avoided treatment due to fear of pain, side effects, or surgery. Third, the increasing adoption of aesthetic dermatology services and the overlap between cosmetic and medical practices are promoting the use of premium treatments like Botox in routine care. Fourth, pharmaceutical companies are investing in next-generation topical formulations and extended-release therapies to cater to unmet needs in focal and generalized hyperhidrosis, enhancing convenience and patient adherence. Fifth, expansion of healthcare coverage, growing telemedicine networks, and the rise of direct-to-consumer digital health brands are making hyperhidrosis treatment more accessible than ever before. Lastly, as patient expectations shift toward holistic, quality-of-life-driven healthcare, the hyperhidrosis treatment market is poised for sustained growth, supported by innovation, awareness, and increasing medical validation.

SCOPE OF STUDY:

The report analyzes the Hyperhidrosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Axillary Hyperhidrosis Type, Palmar Hyperhidrosis Type, Plantar Hyperhidrosis Type, Other Types); Treatment (Topical Treatment, Oral Medication Treatment, Botulinum Toxin Injections Treatment, Iontophoresis Treatment, Surgical Treatment); Age (Below 50 years, Above 50 years); End-User (Hospitals End-User, Ambulatory Surgery Centers End-User, Dermatology Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â